Keyphrases
4-hydroxy-2
5%
Angiotensin II Infusion
9%
Aortic Aneurysm
9%
ApoE KO Mice
8%
Apolipoprotein E Knockout Mice
7%
Aptamer
61%
Bimolecular
28%
Binding Affinity
5%
Blocking Peptide
5%
Bone Anabolic Effects
57%
Bone Formation
49%
Bone Loss
28%
Cardiovascular Protective
28%
Cardiovascular Risk
35%
Cardiovascular System
15%
Chromans
5%
COL1A2
17%
Coupling Agent
5%
Cut-off Threshold
5%
Diet-induced
28%
Dioxo
5%
Druggability
11%
Fibroblast Growth Factor 23 (FGF23)
7%
Glucocorticoid Signaling
8%
Glucose Handling
8%
High-fat Diet
28%
Human Serum Albumin
17%
Hydroxysteroid Dehydrogenase
28%
Inflammatory Chemokines
7%
Inflammatory Cytokines
6%
Large Artery Atherosclerosis
5%
Male Mice
12%
Mechanism Study
5%
Metabolic Disorders
12%
Modification Strategies
28%
Molecular Therapeutics
28%
Molecular Understanding
28%
Nucleic Acid Aptamer
5%
Obesity
28%
Osteoblast
14%
Osteoblastic
28%
Osteogenesis Imperfecta
42%
Pharmacokinetics
5%
Pharmacologic
6%
Postmenopausal Osteoporosis
5%
Propenamide
5%
Protective Behavior
28%
Protective Effect
6%
Pyrrol
5%
Rare Bone Disease
28%
Renal Filtration
5%
Sclerostin
91%
Sclerostin Antibody
10%
Sclerostin Inhibitor
28%
Short Half-life
11%
Synergistic Effect
5%
Synergistic Interaction
11%
Therapeutic Perspectives
28%
Transgenic
5%
Truncation
6%
U.S. Food
5%
Wnt Signaling
7%
X-linked Hypophosphatemia
13%
Pharmacology, Toxicology and Pharmaceutical Science
Angiotensin II
9%
Aortic Aneurysm
8%
Apolipoprotein E
6%
Apolipoprotein E Knockout Mouse
8%
Aptamer
61%
Bone Disease
28%
Cardiovascular Risk
34%
Chemokine
6%
Cytokine
6%
Fibroblast Growth Factor 23
6%
Human Serum Albumin
21%
Ltvax
29%
Nucleic Acid
7%
Osteogenesis Imperfecta
41%
Pharmacokinetic
7%
Sclerostin
100%
X-Linked Hypophosphatemia
12%